# Zealand Pharma clinical trials: 43 (November 2026)

Updated November 19, 2026.

ClinicalTrials.gov lists 43 trials with Zealand Pharma as lead sponsor, 5 of them recruiting or not yet recruiting, as read on November 19, 2026.

## The full list

Clinical trials led by Zealand Pharma: 43 rows for $5, every trial on ClinicalTrials.gov as read on November 19, 2026. Columns: NCT ID, Title, Sponsor, Sponsor class, Phase, Status, Conditions, Condition groups (MeSH), Interventions, Start date, First posted, Last update posted, Enrollment, Location countries, Read on, Source. Pay by card with no account. Prices exclude VAT. CSV and Excel files with the columns this page does not show (sponsor class, condition groups (MeSH), interventions, start date, last update posted and location countries), which open on your screen as soon as the payment clears and come by email. The rows on this page are a sample.

Buy: https://specstream.ai/data/clinical-trials/company/zealand-pharma

SpecStream is the live web data engine for teams and agents. It reads ClinicalTrials.gov each morning, and this page is that reading. Ask for the sponsors, conditions, phases or places you follow and each new or changed trial arrives in your sheet, CRM, Slack or agent with the sponsor, phase, status and sites.

- Trials: 43
- Recruiting or not yet: 5
- Read on: November 19, 2026

## Trials

The 25 newest of 43, each linked to its ClinicalTrials.gov record. The full list holds every one.

| First posted | NCT ID | Title | Sponsor | Phase | Status | Conditions | Enrollment | Source |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| July 29, 2026 | NCT07733089 | A Trial to Understand How Safe and Well Tolerated ZP9830 is and How it Works in People With Plaque Psoriasis Over an 8-week Treatment Period | Zealand Pharma | Phase 1 | Recruiting | Plaque Psoriasis | 32 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07733089) |
| July 23, 2026 | NCT07721597 | A Single and Multiple Ascending Dose Trial Assessing Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of ZP6590 in Participants... | Zealand Pharma | Early phase 1 | Recruiting | Healthy Participants Study, Overweight and Obese Adults, First in Man Study to Evaluate Initial Safety | 88 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07721597) |
| July 6, 2026 | NCT07682818 | Pharmacokinetics of Petrelintide in Participants With Impaired Hepatic Function | Zealand Pharma | Phase 1 | Recruiting | Impaired Hepatic Function | 36 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07682818) |
| January 13, 2026 | NCT07338214 | Investigating the Pharmacokinetics of Petrelintide Using Different Drug Product Concentrations | Zealand Pharma | Phase 1 | Completed | Obesity & Overweight | 48 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07338214) |
| November 14, 2025 | NCT07228403 | Efficacy and Safety Evaluation of Glepaglutide in Treatment of Short Bowel Syndrome | Zealand Pharma | Phase 3 | Active not recruiting | Short Bowel Syndrome (SBS) | 28 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07228403) |
| September 30, 2025 | NCT07197944 | Efficacy And Safety Evaluation of Glepaglutide in Treatment of SBS | Zealand Pharma | Phase 3 | Recruiting | Short Bowel Syndrome | 90 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07197944) |
| July 20, 2025 | NCT07076030 | Pharmacokinetics of Petrelintide Following Administration to Participants With Impaired Renal Function | Zealand Pharma | Phase 1 | Completed | Renal Impairment | 39 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07076030) |
| April 15, 2025 | NCT06926842 | Efficacy and Safety of Petrelintide in Participants With Overweight or Obesity and Type 2 Diabetes (ZUPREME 2) | Zealand Pharma | Phase 2 | Completed | Overweight, Type 2 Diabetes, Obesity | 221 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06926842) |
| January 6, 2025 | NCT06758583 | A Trial Comparing Pharmacokinetics, Safety and Tolerability of Two Subcutaneous Concentrations of Dapiglutide | Zealand Pharma | Phase 1 | Completed | Overweight and Obesity | 30 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06758583) |
| November 12, 2024 | NCT06682975 | A Research Study Looking at the Safety of Single and Multiple Doses of ZP9830 and How it Works in the Body of Healthy Participants | Zealand Pharma | Phase 1 | Recruiting | Healthy Volunteers | 124 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06682975) |
| October 29, 2024 | NCT06662539 | Once-weekly Petrelintide Versus Placebo for Obesity or Overweight With Co-morbidities | Zealand Pharma | Phase 2 | Completed | Obesity | 493 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06662539) |
| August 21, 2023 | NCT06000891 | A Trial Assessing Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of ZP7570 | Zealand Pharma | Phase 1 | Terminated | Safety and Tolerability | 84 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06000891) |
| November 14, 2022 | NCT05613387 | A Research Study Looking at the Safety of Multiple Doses of ZP8396 and How it Works in the Body of Healthy Participants | Zealand Pharma | Phase 1 | Completed | Overweight, Healthy Volunteers, Obese | 68 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05613387) |
| May 18, 2022 | NCT05378672 | A Study to Inv. Safety, Efficacy & PD of Dasiglucagon as Hypoglycemia Rescue Therapy in Children \<6 Years With T1D | Zealand Pharma | Phase 3 | Completed | Hypoglycemia, Type 1 Diabetes | 8 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05378672) |
| October 27, 2021 | NCT05096598 | A First-in-human Study Looking at the Safety of ZP8396 and How it Works in the Body of Healthy Trial Participants | Zealand Pharma | Phase 1 | Completed | Overweight, Healthy Volunteers | 64 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05096598) |
| August 5, 2021 | NCT04991311 | The Long-term Effect on Intestinal Absorption and Safety of Treatment With Glepaglutide in Patients With Short Bowel Syndrome | Zealand Pharma | Phase 3 | Completed | Short Bowel Syndrome | 12 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT04991311) |
| May 11, 2021 | NCT04881825 | Evaluation of Long Term Safety and Efficacy of Glepaglutide in Treatment of SBS - Extension Trial | Zealand Pharma | Phase 3 | Completed | Short Bowel Syndrome | 84 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT04881825) |
| April 1, 2021 | NCT04824872 | Efficacy and Safety of Dasiglucagon for Treatment of Post-bariatric Hypoglycemia in Roux-en-Y Gastric Bypass (RYGB) Operated Adults | Zealand Pharma | Phase 2 | Withdrawn | Hypoglycemia, Glucose Metabolism Disorders | 0 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT04824872) |
| November 3, 2020 | NCT04612517 | A Multiple Ascending Dose Trial Assessing Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of ZP7570 | Zealand Pharma | Early phase 1 | Completed | Healthy | 40 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT04612517) |
| March 24, 2020 | NCT04318743 | A Bridging Trial to Compare the PK Profile When Glepaglutide is Administered Via Vial/Syringe Versus Autoinjector. | Zealand Pharma | Phase 1 | Completed | Healthy | 85 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT04318743) |
| November 26, 2019 | NCT04178447 | Pharmacokinetic Profile of Glepaglutide After a Single Injection in Subjects With Varying Degrees of Renal Function | Zealand Pharma | Phase 1 | Completed | Renal Impairment | 16 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT04178447) |
| November 21, 2019 | NCT04172441 | Trial Evaluating Efficacy and Safety of Dasiglucagon in Children With Congenital Hyperinsulinism | Zealand Pharma | Phase 2/3 | Completed | Congenital Hyperinsulinism | 12 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT04172441) |
| June 21, 2019 | NCT03994549 | A Single Ascending Dose Trial Assessing Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of ZP7570 | Zealand Pharma | Early phase 1 | Completed | Healthy | 64 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT03994549) |
| May 7, 2019 | NCT03941236 | Extension Trial Evaluating the Long-term Safety and Efficacy of Dasiglucagon in Children With Congenital Hyperinsulinism | Zealand Pharma | Phase 3 | Completed | Congenital Hyperinsulinism | 42 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT03941236) |
| April 5, 2019 | NCT03905707 | Evaluation of Long Term Safety and Efficacy of Glepaglutide in Treatment of SBS | Zealand Pharma | Phase 3 | Completed | Short Bowel Syndrome | 150 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT03905707) |

## By phase

| Phase | Trials |
| --- | --- |
| Early phase 1 | 3 |
| Phase 1 | 16 |
| Phase 2 | 9 |
| Phase 2/3 | 1 |
| Phase 3 | 14 |

## By status

| Status | Trials |
| --- | --- |
| Completed | 34 |
| Recruiting | 5 |
| Terminated | 2 |
| Withdrawn | 1 |
| Active not recruiting | 1 |

## Conditions

| Condition group | Trials |
| --- | --- |
| Hypoglycemia | 11 |
| Overweight | 7 |
| Obesity | 7 |
| Short Bowel Syndrome | 7 |
| Diabetes Mellitus, Type 1 | 7 |
| Congenital Hyperinsulinism | 3 |
| Diabetes Mellitus | 2 |
| Renal Insufficiency | 2 |
| Malabsorption Syndromes | 2 |
| Intestinal Diseases | 2 |
| Gastrointestinal Diseases | 2 |
| Digestive System Diseases | 2 |
| Postoperative Complications | 2 |
| Pathologic Processes | 2 |
| Glucose Metabolism Disorders | 1 |
| Pathological Conditions, Signs and Symptoms | 1 |
| Heart Failure | 1 |
| Diabetes Mellitus, Type 2 | 1 |
| Intestinal Failure | 1 |
| Syndrome | 1 |
| Inflammatory Bowel Diseases | 1 |

## Where the register publishes

- [ClinicalTrials.gov](https://clinicaltrials.gov/)
- [ClinicalTrials.gov API](https://clinicaltrials.gov/data-api/api)

Source: [ClinicalTrials.gov API v2 (U.S. National Library of Medicine)](https://clinicaltrials.gov/data-api/api). U.S. government data; ClinicalTrials.gov terms of use. Studies are as their sponsors registered them on ClinicalTrials.gov, read through its API. Recruiting means the record's overall status is recruiting or not yet recruiting. Condition groups are the MeSH terms ClinicalTrials.gov assigns; a condition page also counts the narrower terms that name it, as the register's own search does (triple negative breast neoplasms are breast neoplasms). Sites are shown as organizations only; no investigator or contact is read or shown.

Free to quote with credit and a link. Copying in bulk needs a [data licence](https://specstream.ai/data/licence).

## Business lists in the United States

- [Basque restaurants in the United States](https://specstream.ai/data/businesses/basque-restaurants/united-states)
- [Fastener suppliers in the United States](https://specstream.ai/data/businesses/fastener-suppliers/united-states)
- [Mills in the United States](https://specstream.ai/data/businesses/mills/united-states)
- [Stone and masonry companies in the United States](https://specstream.ai/data/businesses/stone-and-masonry-companies/united-states)
- [Bar and grill restaurants in the United States](https://specstream.ai/data/businesses/bar-and-grill-restaurants/united-states)
- [Farm insurance companies in the United States](https://specstream.ai/data/businesses/farm-insurance-companies/united-states)
